 3.2	Body of data
 3.2.S	Drug substance {{name}}, {{manufacturer}}
 3.2.S.1	General information
 3.2.S.1.1	Nomenclature
 3.2.S.1.2	Structure
 3.2.S.1.3	General properties
 3.2.S.2	Manufacture
 3.2.S.2.1	Manufacturer(s)
 3.2.S.2.2	Description of Manufacturing Process and Process Controls
 3.2.S.2.3	Control of Materials
 3.2.S.2.4	Controls of Critical Steps and Intermediates
 3.2.S.2.5	Process Validation and/or Evaluation
 3.2.S.2.6	Manufacturing Process Development
 3.2.S.3	Characterization
 3.2.S.3.1	Elucidation of Structure and other Characteristics
 3.2.S.3.2	Impurities
 3.2.S.4	Control of drug substance
 3.2.S.4.1	Specification
 3.2.S.4.2	Analytical Procedures
 3.2.S.4.3	Validation of Analytical Procedures
 3.2.S.4.4	Batch Analyses
 3.2.S.4.5	Justification of Specification
 3.2.S.5	Reference standards or materials
 3.2.S.6	Container closure systems
 3.2.S.7	Stability
 3.2.S.7.1	Stability Summary and Conclusions
 3.2.S.7.2	Post Approval Stability Protocol and Stability Commitment
 3.2.S.7.3	Stability Data
 3.2.P	Drug product {{name}}, {{dosage form}}, {{manufacturer}}
 3.2.P.1	Description and composition of the drug product
 3.2.P.2	Pharmaceutical development
 3.2.P.3	Manufacture
 3.2.P.3.1	Manufacturer(s)
 3.2.P.3.2	Batch Formula
 3.2.P.3.3	Description of Manufacturing Process and Process Controls
 3.2.P.3.4	Controls of Critical Steps and Intermediates
 3.2.P.3.5	Process Validation and/or Evaluation
 3.2.P.4	Control of excipients [{{name}}]
 3.2.P.4.1	Specification(s)
 3.2.P.4.2	Analytical Procedures
 3.2.P.4.3	Validation of Analytical Procedures
 3.2.P.4.4	Justification of Specifications
 3.2.P.4.5	Excipients of Human or Animal Origin
 3.2.P.4.6	Novel Excipients
 3.2.P.5	Control of drug product
 3.2.P.5.1	Specification(s)
 3.2.P.5.2	Analytical Procedures
 3.2.P.5.3	Validation of Analytical Procedures
 3.2.P.5.4	Batch Analyses
 3.2.P.5.5	Characterization of Impurities
 3.2.P.5.6	Justification of Specification(s)
 3.2.P.6	Reference standards or materials
 3.2.P.7	Container closure system
 3.2.P.8	Stability
 3.2.P.8.1	Stability Summary and Conclusion
 3.2.P.8.2	Postapproval Stability Protocol and Stability Commitment
 3.2.P.8.3	Stability Data
 3.2.A	Appendices
 3.2.A.1	Facilities and Equipment [{{name}}, {{manufacturer}}]
 3.2.A.2	Adventitious agents safety evaluation [{{name}}, {{dosage form}}, {{manufacturer}}]
 3.2.A.3	Novel excipients
 3.2.R	Regional information